要闻！企业标准备案虚假宣传乱象整治：市场监管总局出击 打造诚信规范市场环境

企业标准备案虚假宣传乱象整治：市场监管总局出击 打造诚信规范市场环境

北京讯 近期，市场监管总局加大对企业标准备案虚假宣传行为的整治力度，严肃查处了一批违法违规企业，取得了显著成效。此举旨在规范企业标准管理，维护市场秩序，保护消费者权益，为营造诚信规范的市场环境打下坚实基础。

虚假宣传手段多样 严重扰乱市场秩序

一些企业为了牟取不正当利益，编造虚假信息，以“国家标准化管理委员会标准备案企业”等名义进行虚假宣传，误导消费者和公众。这些虚假宣传手段多样，包括：

• 在企业官网、宣传资料、产品包装上印制虚假标注，声称获得国家标准化管理委员会认可或认证；
• 冒用国家标准化管理委员会或其他相关机构名义，颁发虚假证书或牌匾；
• 在网络平台上发布虚假信息，谎称企业标准通过了国家标准化管理委员会的审核。

这些虚假宣传行为严重扰乱了市场秩序，损害了消费者权益，也对政府公信力造成了不良影响。

市场监管总局组合拳出击 严厉打击违法行为

为整治企业标准备案虚假宣传行为，市场监管总局采取了多项措施，形成了“组合拳”效应：

• 开展梳理排查：组织全国组织机构统一社会信用代码数据服务中心，对企标平台疑似存在虚假宣传行为的企业逐项梳理、建立台账。
• 及时发出警示：通过企标平台发布警示信息，提醒企业、公众注意防范。
• 畅通举报渠道：明确举报途径方法，鼓励企业、公众积极监督举报。
• 严肃处理整治：责令涉事企业限时整改，并在企标平台进行公示。

截至2024年5月，市场监管总局共发现并处置了17起涉嫌以“国家标准化管理委员会标准备案企业”等名义虚假宣传的不良行为，相关情况得到有效遏制。

企业应诚信经营 消费者应提高警惕

市场监管总局提醒广大企业要诚信经营，严格遵守相关法律法规，杜绝虚假宣传行为。同时，消费者也应提高警惕，通过正规渠道查询企业信息，不要轻信虚假宣传，必要时可向市场监管部门举报。

整治企业标准备案虚假宣传行为是一项长期的任务，需要多方共同努力。市场监管部门将持续加大执法力度，严厉打击违法违规行为，为营造诚信规范的市场环境提供有力保障。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.